Stock Events

Stock Events

Syndax Pharmaceuticals 

$22.64
59
+$0.35+1.57% Tuesday 20:00
+$0.00+0%Tuesday 23:34After hours

Statistics

Day High
22.66
Day Low
22.62
52W High
25.59
52W Low
9.42
Volume
63,083
Avg. Volume
-
Mkt Cap
2.01B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-1.25
-0.99
-0.73
-0.47
Expected EPS
-0.474535
Actual EPS
N/A

Financials

-165.6%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
172.35MRevenue
-285.42MNet Income

Analyst Ratings

41.63Average Price Target
The highest estimate is 57.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SNDX. It's not an investment recommendation.
Amazon
15
AMZN
Apple
13
AAPL
Microsoft
13
MSFT
AMD
13
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. competes in the oncology space with its range of cancer treatments, potentially overlapping with Syndax's focus on cancer therapeutics.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol-Myers Squibb Company offers a portfolio of cancer drugs, directly competing with Syndax Pharmaceuticals in the oncology market.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca PLC has a strong presence in developing cancer treatments, including therapies that may compete with Syndax's pipeline.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. has a broad range of oncology products that could compete with Syndax Pharmaceuticals' cancer therapies.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, Inc. is involved in the development of oncology and hematology drugs, areas where Syndax is also aiming to make an impact.
AMGEN
AMGN
Mkt Cap196.12B
Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies that could rival Syndax's cancer treatment solutions.
Novartis
NVS
Mkt Cap293.94B
Novartis AG has a diversified portfolio in oncology, potentially competing with Syndax Pharmaceuticals in multiple areas of cancer treatment.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, develops cancer drugs that could be in direct competition with Syndax's offerings.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including cancer treatments that may compete with Syndax.
Exelixis
EXEL
Mkt Cap14.2B
Exelixis, Inc. is focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers, directly competing with Syndax Pharmaceuticals.

About

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Show more...
CEO
Mr. Michael A. Metzger M.B.A.
Employees
298
Country
United States
ISIN
US87164F1057

Listings

F
DE
1T3.F
STU
DE
1T3.STU
MU
DE
1T3.MU
XNAS
US
SNDX

0 Comments

Share your thoughts

FAQ

What is Syndax Pharmaceuticals stock price today?▼
The current price of SNDX is $22.64 USD — it has increased by +1.57% in the past 24 hours. Watch Syndax Pharmaceuticals stock price performance more closely on the chart.
What is Syndax Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Syndax Pharmaceuticals stocks are traded under the ticker SNDX.
Is Syndax Pharmaceuticals stock price growing?▼
SNDX stock has fallen by -3.74% compared to the previous week, the month change is a +17.18% rise, over the last year Syndax Pharmaceuticals has showed a +119.59% increase.
What is Syndax Pharmaceuticals market cap?▼
Today Syndax Pharmaceuticals has the market capitalization of 2.01B
When is the next Syndax Pharmaceuticals earnings date?▼
Syndax Pharmaceuticals is going to release the next earnings report on August 10, 2026.
What were Syndax Pharmaceuticals earnings last quarter?▼
SNDX earnings for the last quarter are -0.48 USD per share, whereas the estimation was -0.61 USD resulting in a +21.02% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Syndax Pharmaceuticals revenue for the last year?▼
Syndax Pharmaceuticals revenue for the last year amounts to 172.35M USD.
What is Syndax Pharmaceuticals net income for the last year?▼
SNDX net income for the last year is -285.42M USD.
How many employees does Syndax Pharmaceuticals have?▼
As of July 22, 2026, the company has 298 employees.
In which sector is Syndax Pharmaceuticals located?▼
Syndax Pharmaceuticals operates in the Health & Wellness sector.
When did Syndax Pharmaceuticals complete a stock split?▼
Syndax Pharmaceuticals has not had any recent stock splits.
Where is Syndax Pharmaceuticals headquartered?▼
Syndax Pharmaceuticals is headquartered in New York, United States.